<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003005</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065572</org_study_id>
    <secondary_id>BUMC-4266</secondary_id>
    <secondary_id>NCI-T96-0051</secondary_id>
    <nct_id>NCT00003005</nct_id>
  </id_info>
  <brief_title>Chemotherapy With Cordycepin Plus Pentostatin in Treating Patients With Refractory Acute Lymphocytic or Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase I Study of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) in Patients With Refractory TdT-Positive Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of chemotherapy consisting of cordycepin
      plus pentostatin in treating patients with refractory acute lymphocytic or chronic
      myelogenous leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the safety, maximum tolerated dose, adverse effects, and toxicities
      of cordycepin, given 1 hour following a fixed dose of the adenosine deaminase inhibitor
      pentostatin, in patients with refractory TdT positive leukemia. II. Determine the single and
      multiple dose pharmacokinetics of cordycepin given 1 hour following a fixed dose of
      pentostatin. III. Characterize selected whole blood and blast cell metabolic parameters
      serially in relation to cordycepin/pentostatin administration. IV. Measure and quantify any
      clinical responses in refractory TdT positive leukemia patients following
      cordycepin/pentostatin administration.

      OUTLINE: This is a dose escalation study. Each treatment course is 28 days in length. On days
      1-3 pentostatin is administered over 5 minutes by IV bolus and followed 1 hour later by a 1
      hour infusion of cordycepin IV. An escalating dose of pentostatin is given with a fixed dose
      of cordycepin until the desired level of adenosine deaminase inhibition is observed. After
      this is determined, a dose escalation schedule for cordycepin is initiated to determine the
      maximum tolerated dose (MTD) when given in combination with pentostatin. The MTD is
      determined by the number of patients who exhibit dose limiting toxicity and the severity of
      the toxicity.

      PROJECTED ACCRUAL: Approximately 30 patients will be accrued.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1997</start_date>
  <completion_date type="Actual">March 2001</completion_date>
  <primary_completion_date type="Actual">March 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>28 days</time_frame>
    <description>Dose limiting toxicities will be assessed within the first 28 days of study drug</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>deoxycoformycin and cordycepin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation for deoxycoformycin and cordycepin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cordycepin</intervention_name>
    <description>Dose escalation study using the following doses:
6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2</description>
    <arm_group_label>deoxycoformycin and cordycepin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deoxycoformycin</intervention_name>
    <description>Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous</description>
    <arm_group_label>deoxycoformycin and cordycepin</arm_group_label>
    <other_name>pentostatin, dCF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: TdT positive acute lymphocytic leukemia or blastic chronic
        myelogenous leukemia Failed at least one standard treatment

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky greater than 70%
        Life expectancy: At least 3 months Hematopoietic: Not specified Hepatic: Bilirubin no
        greater than 2.0 mg/dL Transaminases no greater than 2.5 times normal Renal: Creatinine no
        greater than 1.5 mg/dL Creatinine clearance greater than 60 mL/min Cardiovascular: Ejection
        fraction greater than 40% Other: Not pregnant or nursing No serious concurrent illness

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks
        since chemotherapy No concurrent chemotherapy Endocrine therapy: Not specified
        Radiotherapy: At least 3 weeks since radiation therapy Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J. Ernst, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vincent T. Lombardi Cancer Research Center, Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Medical Center Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Barnard Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital - Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Cancer Center at Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2004</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>TdT positive adult acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cordycepin</mesh_term>
    <mesh_term>Pentostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

